Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Goldhirsch, 2011, Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 22, 1736, 10.1093/annonc/mdr304

The Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412

Dunbier, 2011, Association between breast cancer subtypes and response to neoadjuvant anastrozole, Steroids, 76, 736, 10.1016/j.steroids.2011.02.025

Ellis, 2012, Whole-genome analysis informs breast cancer response to aromatase inhibition, Nature, 486, 353, 10.1038/nature11143

Galimberti, 2012, Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?, Breast Cancer Res Treat, 131, 819, 10.1007/s10549-011-1486-2

Martelli, 2012, Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial, Ann Surg, 256, 920, 10.1097/SLA.0b013e31827660a8

A Goldhirsch RD Gelber MJ Piccart-Gebhart. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialThe Lancet 2013 July 18 [epub ahead of print] doi: 10.1016/S0140-6736(13)61094-6

Pivot, 2013, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol, 14, 741, 10.1016/S1470-2045(13)70225-0

Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1

Baselga, 2012, Everolimus in postmenopausalhormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653

Osborne, 2013, Overcoming resistance to endocrine therapy due to PI3K/AKT pathway activation by combinations of mTOR, AKT or MEK inhibitors, The Breast, 22, S2

Ibrahim, 2012, PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition, Cancer Discov, 2, 1036, 10.1158/2159-8290.CD-11-0348

Juvekar, 2012, Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer, Cancer Discov, 2, 1048, 10.1158/2159-8290.CD-11-0336

Varna, 2011, TP53 status and response to treatment in breast cancers, J Biomed Biotechnol, 10.1155/2011/284584

Jackson, 2012, p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer, Cancer Cell, 21, 793, 10.1016/j.ccr.2012.04.027

Bailey, 2012, Estrogen receptor prevents p53-dependent apoptosis in breast cancer, Proc Natl Acad Sci USA, 109, 18060, 10.1073/pnas.1018858109

Bonnefoi, 2011, TP53 Status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1–00): a randomised phase 3 trial, Lancet Oncol, 12, 527, 10.1016/S1470-2045(11)70094-8

Early Breast Cancer Trialists’ Collaborative Group, 2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials, Lancet, 379, 432, 10.1016/S0140-6736(11)61625-5

Di Leo, 2013, The continued evidence from overviews: what is the clinical utility?, The Breast, 22, S2

Ellis, 2013, The genomic landscape of breast cancer as a therapeutic roadmap, Cancer Discov, 3, 27, 10.1158/2159-8290.CD-12-0462

Hayes, 2013, From the genome to bedside: are we lost in translation?, The Breast, 22, S3

Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370

Cheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082

Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134

Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393

TO Nielsen M-YC Polley SCY Leung. An international Ki-67 reproducibility study. Presented at the 35th San Antonio Breast Cancer SymposiumDecember 4–8, 2012Abstr S4–6

Luporsi, 2012, Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, 132, 895, 10.1007/s10549-011-1837-z

Buckland, 2013, Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study, Int J Cancer, 132, 2918, 10.1002/ijc.27958

Chlebowski, 2013, Nutrition and physical activity influence on breast cancer incidence and recurrence, The Breast, 22, S5

Folkerd, 2012, Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer, J Clin Oncol, 30, 2977, 10.1200/JCO.2012.42.0273

Dowsett, 2013, Sex hormones and breast cancer risk and prognosis, The Breast, 22, S5

Mavaddat, 2012, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA), Cancer Epidemiol Biomarkers Prev, 21, 134, 10.1158/1055-9965.EPI-11-0775

Niraula, 2012, Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis, Breast Cancer Res Treat, 134, 769, 10.1007/s10549-012-2073-x

Sestak, 2010, Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial, J Clin Oncol, 28, 3411, 10.1200/JCO.2009.27.2021

Ewertz, 2012, Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1–98 trial, J Clin Oncol, 30, 3967, 10.1200/JCO.2011.40.8666

Goodwin, 2010, Obesity and hormone therapy in breast cancer: an unfinished puzzle, J Clin Oncol, 28, 3405, 10.1200/JCO.2010.29.5113

Pfeiler, 2011, Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial, J Clin Oncol, 29, 2653, 10.1200/JCO.2010.33.2585

Bertolini, 2013, Adipose tissue and breast cancer progression: a link between metabolism and cancer, The Breast, 22, S6

Bertolini, 2012, Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons, Biochim Biophys Acta, 1826, 209

Petit, 2012, Locoregional recurrence risk after lipofilling in breast cancer patients, Ann Oncol, 23, 582, 10.1093/annonc/mdr158

Oskarsson, 2011, Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs, Nat Med, 17, 867, 10.1038/nm.2379

Oskarsson, 2013, Extracellular matrix players in breast cancer progression and metastasis, The Breast, 22, S7

Coleman, 2011, Breast-cancer adjuvant therapy with zoledronic acid, N Engl J Med, 365, 1396, 10.1056/NEJMoa1105195

Coleman, 2013, Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results, Ann Oncol, 24, 398, 10.1093/annonc/mds277

Gnant, 2011, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, Lancet Oncology, 12, 631, 10.1016/S1470-2045(11)70122-X

Goldhirsch, 2013, Personalized adjuvant therapies: lessons from the past, The Breast, 22, S1

Kerbel, 2013, Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis, The Breast, 22, S7

Hassett, 2012, Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer, J Clin Oncol, 30, 2218, 10.1200/JCO.2011.38.5740

Drukker, 2013, A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study, Int J Cancer, 131, 929, 10.1002/ijc.28082

Pusztai, 2013, Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer, The Breast, 22, S9

Nielsen, 2010, A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer, Clin Cancer Res, 16, 5222, 10.1158/1078-0432.CCR-10-1282

Dubsky, 2013, Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer, Ann Oncol, 24, 640, 10.1093/annonc/mds334

DS groi I Sestak J Cuzick. Comparative performance of breast cancer index (BCI) versus oncotype DX and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node negative breast cancer patients: a transATAC study. Presented at the 35th San Antonio Breast Cancer Symposium, December 4–8, 2012 (Abstr S1–9).

Viale, 2013, Characterization and clinical impact of residual disease after neoadjuvant chemotherapy, The Breast, 22, S9

von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595

Loi, 2013, Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98, J Clin Oncol, 31, 860, 10.1200/JCO.2011.41.0902

Andre, 2013, Risk stratification for treatment choice: opportunities, challenges and tools, The Breast, 22, S10

Sotiriou, 2013, Immune signatures: prognostic and predictive role in breast cancer, The Breast, 22, S11

Curigliano, 2013, Developing an effective breast cancer vaccine, The Breast, 22, S10

Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370

Morrow, 2013, Personalizing extent of breast cancer surgery according to molecular subtypes, The Breast, 22, S12

Kiess, 2012, Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer, Cancer, 118, 1982, 10.1002/cncr.26484

Rutgers, 2013, Who should not undergo breast conservation?, The Breast, 22, S13

Wood, 2013, Close/positive margins after breast-conserving therapy, The Breast, 22, S13

Galimberti, 2013, Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial, Lancet Oncol, 14, 297, 10.1016/S1470-2045(13)70035-4

Giuliano, 2011, Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis, JAMA, 305, 569, 10.1001/jama.2011.90

Gentilini, 2012, Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node versus observation after axillary UltraSouND), Breast, 21, 678, 10.1016/j.breast.2012.06.013

Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260

JR Yarnold. The UK START (standardisation of breast radiotherapy) trials: 10-year follow-up results. Presented at the 35th San Antonio Breast Cancer Symposium, December 4–8, 2012 (Abstr. S4–1).

Harris, 2013, Hypofractionation in the era of modulated radiotherapy, The Breast, 22, S14

Orecchia, 2013, Partial breast irradiation: targeting volume or breast molecular subtypes?, The Breast, 22, S14

Smith, 2009, Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO), Int J Radiat Oncol Biol Phys, 74, 987, 10.1016/j.ijrobp.2009.02.031

Polgar, 2010, Radiother Oncol, 94, 264, 10.1016/j.radonc.2010.01.014

Sedlmayer, 2013, Partial breast re-irradiation for local recurrence of breast carcinoma: benefit and potential long term side effects, The Breast, 22, S15

Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985

Albain, 2010, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 11, 55, 10.1016/S1470-2045(09)70314-6

Cheang, 2012, Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial, Clin Cancer Res, 18, 2402, 10.1158/1078-0432.CCR-11-2956

Burstein, 2013, Patients with triple-negative breast cancer: is there an optimal adjuvant treatment?, The Breast, 22, S16

Colleoni, 2013, Extended adjuvant chemotherapy in endocrine non-responsive disease, The Breast, 22, S17

von Minckwitz, 2013, Selecting the neoadjuvant treatment by molecular subtype: how to maximise the benefit, The Breast, 22, S16

Gianni, 2005, Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer, J Clin Oncol, 23, 7265, 10.1200/JCO.2005.02.0818

Straver, 2010, The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, Breast Cancer Res Treat, 119, 551, 10.1007/s10549-009-0333-1

Piccart, 2013, Patients with HER2 positive breast cancer: delivery, duration and combination therapies, The Breast, 22, S16

Davidson, 2013, Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer, The Breast, 22, S18

Goss, 2003, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, 1793, 10.1056/NEJMoa032312

Goss, 2013, Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole, Ann Oncol, 24, 355, 10.1093/annonc/mds330

Ingle, 2013, Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors, The Breast, 22, S19

Amir, 2011, Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis, J Natl Cancer Inst, 103, 1299, 10.1093/jnci/djr242

Clarke, 2012, Age-specific incidence of breast cancer subtypes: understanding the black-white crossover, J Natl Cancer Inst, 104, 1094, 10.1093/jnci/djs264

S Loibl C Jackisch S Gade. Neoadjuvant chemotherapy in the very young, 35 years of age or younger. Presented at the 35th San Antonio Breast Cancer Symposium, December 4–8, 2012 (Abstr. S3–1).

Partridge, 2013, Management of breast cancer in the very young, The Breast, 22, S18

Smith, 2013, Follow-up tests to detect recurrent disease: patient's reassurance or medical need?, The Breast, 22, S17

Hayes, 2012, Targeting adjuvant chemotherapy: a good idea that needs to be proven!, J Clin Oncol, 30, 1264, 10.1200/JCO.2011.38.4529

Coates, 2012, Is adjuvant chemotherapy useful for women with luminal A breast cancer?, J Clin Oncol, 30, 1260, 10.1200/JCO.2011.37.7879

Prat, 2012, Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen, Ann Oncol, 23, 2866, 10.1093/annonc/mds080

Regan, 2008, Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?, Ann Oncol, 19, 1231, 10.1093/annonc/mdn037

Wirapati, 2008, Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures, Breast Cancer Res, 10, R65, 10.1186/bcr2124

Reed, 2013, Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer, Genet Med, 15, 203, 10.1038/gim.2012.119

Vanderlaan, 2011, Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer, Am J Manag Care, 17, 455

Davidson, 2013, A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene recurrence score(R) assay in oestrogen receptor positive node negative breast cancer, Eur J Cancer, 10.1016/j.ejca.2013.03.009

Hannouf, 2012, Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer, BMC Cancer, 12, 447, 10.1186/1471-2407-12-447

Lamond, 2012, Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer, Breast Cancer Res Treat, 133, 1115, 10.1007/s10549-012-1989-5

Tsoi, 2010, Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer, Oncologist, 15, 457, 10.1634/theoncologist.2009-0275

Hornberger, 2005, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am J Manag Care, 11, 313

Klang, 2010, Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization, Value Health, 13, 381, 10.1111/j.1524-4733.2010.00724.x

Hall, 2012, Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer, J Natl Cancer Inst, 104, 56, 10.1093/jnci/djr484

Blohmer, 2013, Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting, J Med Econ, 16, 30, 10.3111/13696998.2012.722572

Eiermann, 2013, The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use, Ann Oncol, 24, 618, 10.1093/annonc/mds512

Kondo, 2012, Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan, Breast Cancer Res Treat, 133, 759, 10.1007/s10549-012-1979-7

Sahin, 1991, Ki-67 immunostaining in node-negative stage I/II breast carcinoma: significant correlation with prognosis, Cancer, 68, 549, 10.1002/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J

Railo, 1997, Ki-67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer, Acta Oncol, 36, 369, 10.3109/02841869709001282

Jansen, 1998, MIB-1 labelling index is an independent prognostic marker in primary breast cancer, Br J Cancer, 78, 460, 10.1038/bjc.1998.515

Mirza, 2002, Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years, Ann Surg, 235, 10, 10.1097/00000658-200201000-00003

Trihia, 2003, Ki-67 expression in breast carcinoma, Cancer, 97, 1321, 10.1002/cncr.11188

de Azambuja, 2007, Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients, Br J Cancer, 96, 1504, 10.1038/sj.bjc.6603756

Dowsett, 2007, Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer, J Natl Cancer Inst, 99, 167, 10.1093/jnci/djk020

Viale, 2008, Value of Ki-67 in two randomized trials of adjuvant chemo-endocrine therapies for node-negative breast cancer, J Natl Cancer Inst, 100, 207, 10.1093/jnci/djm289

Viale, 2008, Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group trial 1–98 comparing adjuvant tamoxifen with letrozole, J Clin Oncol, 26, 5569, 10.1200/JCO.2008.17.0829

Muss, 2009, Adjuvant chemotherapy in older women with early stage breast cancer, N Engl J Med, 360, 2055, 10.1056/NEJMoa0810266